COVID-19 has had a significant impact on testing and identification and has forced rapid restructuring in hospital-wide and ambulatory settings. Telemedicine has been incorporated into clinical workflows, with much preventive care, including hepatitis C virus (HCV) testing, not being routinely performed. Hospital-wide, total HCV testing has decreased by 49.6% and new HCV-positive patient identification has decreased by an alarming 42.1%. Ambulatory clinic testing has decreased by a staggering 71.9% and new HCV-positive patient identification has decreased by 63.3%. The COVID-19 systematic emergency response has led to decreased HCV testing and identification, with telemedicine being a barrier to HCV care.
This CME Outfitters Newsletter article features insight on the challenges, consequences, and opportunities created by COVID-19 in the testing and treatment rates of HCV globally.
At the end of this CME/CE activity, participants should be able to apply CDC universal screening guidelines to improve diagnosis of HCV and linkage to treatment
Those requesting CNE or CPE credit should be able to describe the CDC universal screening guidelines to improve diagnosis of HCV and linkage to treatment.
Supported by an educational grant from Gilead Sciences, Inc.
Primary care physicians, emergency medicine physicians, addiction specialists, PAs, nurse practitioners, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CECE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gold has no disclosures to report.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-075-H01-P